ESMO 2022 Conference Coverage
ESMO 2022 on the Randomized Phase 3 FORWARD I Study: Analyses of Patient-Reported Outcomes With Mirvetuximab Soravtansine vs. Standard Chemo in Ovarian Cancer
By
ESMO 2022 Conference Coverage
FEATURING
Kathleen Moore
By
ESMO 2022 Conference Coverage
FEATURING
Kathleen Moore
Login to view comments.
Click here to Login
GYN